Find and Pitch Jounalists, Get Your Story Covered

Tags: osimertinib amivantamab egfr inhibitor lung cancer liquid

	Profile	Recent Articles on Subject
1	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Mutation Clearance After Transplant Linked to Better Outcomes in Myelofibrosis - 14 days ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 5 months ago FDA Approves Belzutifan for Advanced Renal Cell Carcinoma - about 1 year ago Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations - about 1 year ago FDA OKs New Option for Advanced ROS1-Positive Lung Cancer - about 1 year ago RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer - about 1 year ago RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC - about 1 year ago
2	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	EC approves Rybrevant with Lazcluze for advanced lung cancer - 20 days ago Bayer begins inhibitor study treating advanced KRAS-mutated tumours - about 1 month ago MHRA grants approval for bladder cancer drug erdafitinib - 3 months ago
3	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Antibody Drug Conjugate Targeting CLDN1 Receives FDA Fast Track Designation - 2 months ago CHMP Recommends Lazertinib With Amivantamab to Treat EGFR-Mutated Advanced NSCLC - 2 months ago Adagrasib Meets Primary Endpoint Among Individuals with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC - 10 months ago Phase 3 EVOKE-01 Study in Metastatic NSCLC Falls Short of Primary Endpoint - 11 months ago
4	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FLASCO Fall Session: Advancements in MRD Monitoring Using ctDNA in Lung Cancer - 3 months ago Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials - 4 months ago Embracing a Precision Medicine Approach to KRAS G12C–Mutated Advanced NSCLC With Adagrasib - 10 months ago FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy - 10 months ago
5	Kristen Monaco MedPage Today	Complement Inhibitor Shows Promise for Rare Kidney Disorder - 3 months ago Sparsentan Failed to Preserve Kidney Function Over Time in FSGS - about 1 year ago
6	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Exploratory Analysis Shows Favorable Outcomes for Amivantamab-Lazertinib Treatment in NSCLC - 4 months ago Study: Mutation Found to Make Follicular Lymphoma More Susceptible to Experimental Drug - 10 months ago FDA Accepts Supplemental New Drug Application for Adagrasib for Colorectal Cancer - 11 months ago FDA Approves Osimertinib With Chemotherapy for EGFRm NSCLC - 11 months ago FDA Approves Belzutifan for Treatment of Advanced Renal Cell Carcinoma - about 1 year ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - about 1 year ago FDA Approves Repotrectinib for Treatment of ROS1-Positive NSCLC - about 1 year ago FDA Grants Priority Review to New Drug Application for Belzutifan for Advanced Renal Cell Carcinoma - over 1 year ago
7	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Novel TKI Promising in Early Study of HER2-Mutant NSCLC - 7 months ago Novel Doublet Highly Effective in Low-Grade Serous Ovarian Cancer - about 1 year ago
8	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	FDA OKs Amivantamab as First-Line Lung Cancer Treatment - 11 months ago New Oral Drug Approved for Metastatic Colorectal Cancer - about 1 year ago New Options Challenge Standard Treatments in EGFR-Mutant NSCLC - about 1 year ago Randomized Trial Backs HIF-2a Inhibition in Advanced RCC - about 1 year ago
9	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	FDA Grants Priority Review to Repotrectinib for the Treatment of NTRK-Positive Solid Tumors - 11 months ago
10	Randy Dotinga MedPage Today Indie scribbler, advocate. Board member, @ahcj. San Diego WritingAdvocacy	EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk - about 1 year ago

Journalists covering EGFR mutations